Ironwood Pharmaceuticals, Inc.
IRWD
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as uā¦ read more
Healthcare
Drug ManufacturersāSpecialty & Generic
16 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$4.35
Price+0.93%
$0.04
1Y
Price
Market Cap
$716.067m
Small
Price/Earnings 3y Avg5y Avg
5.6x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+70.2%
EBITDA Margin+38.3%
Net Profit Margin+4.8%
Free Cash Flow Margin+70.2%
EBITDA Margin+38.3%
Net Profit Margin+4.8%
Free Cash Flow MarginRevenue
$361.514m
+22.1%
1y CAGR-4.8%
3y CAGR-1.6%
5y CAGREarnings
$102.176m
+325.4%
1y CAGR+1018.2%
3y CAGR+595.6%
5y CAGREPS
$0.60
+300.0%
1y CAGR+600.1%
3y CAGR+257.1%
5y CAGRBook Value
-$217.144m
$434.566m
Assets$651.710m
Liabilities$597.356m
DebtDebt to Assets
137.5%
2.9x
Debt to EBITDAFree Cash Flow
$112.208m
-11.6%
1y CAGR-10.8%
3y CAGR-16.4%
5y CAGRNo items found.
Press Releases
Statements and updates from the company